I am not affiliated with Peptide Sciences or with any provider named here, and nothing in this piece links to an order page. The links below go to sources you can check for yourself: an independent ranking, a regulatory-law breakdown, the documented FDA actions, and the underlying clinical studies. Compounded or prescribed peptides named here are not FDA-approved, and “research use only” products are not approved for human use at all. June 2026.
Picture the week this actually happens to someone. She reorders on a Tuesday like always, gets a shipping error, shrugs it off, tries again Thursday, and by Friday night she’s typing “Peptide Sciences shut down” into a search bar at eleven o’clock with a half-empty vial in the fridge and a real question underneath the panic: now what do I do with my body?
That’s who this piece is for. Not the biohacking forums, not the people who enjoy a good regulatory rabbit hole for its own sake, but the person who had a routine that worked for her and now has a gap where a supplier used to be. If that’s you, the good news is that the gap is fillable. The uncomfortable news is that most of what will show up in your search results this week isn’t built to fill it responsibly, and the only way to tell the difference is to ask each option the same five questions and actually wait for an answer.
What the science, and the paper trail, actually say
I spent a stretch of this year doing something tedious on purpose: instead of comparing peptide sellers by price or shipping speed, the way most roundups do, I built a five-point scorecard and made every provider I could find sit for it. Oversight, sourcing, visible testing, honesty about what’s approved and what isn’t, and follow-up after the first order. No points for a slick homepage.
Two things reshaped how I read the results, and they’re worth carrying into your own week of tab-hopping.
The first is soft, so I’ll treat it that way. Peptide Sciences going dark in early 2026 is widely reported, but I couldn’t confirm it against any government filing, only independent analysts and a lot of affiliate chatter. Anyone giving you precise numbers on the shutdown is guessing [C1].
The second is hard and documented, and it’s the one that actually changed my scoring. On March 31, 2026, the FDA sent warning letters to a group of online peptide sellers, including Gram Peptides and Prime Sciences, calling their products unapproved new drugs and dismissing the “research use only” label outright. The agency’s own words: “Evidence obtained from your website establishes that your products are intended to be drugs for human use” [C4]. It wasn’t an isolated shot, either. A regulatory-law review counted more than fifty FDA warning letters in a single stretch in September 2025, aimed at compounded GLP-1 marketing and at peptides “being sold as ‘research use only’ where the advertising indicated the product was intended for human use” [C5].
Sit with what that means for the person in the Tuesday-night-fridge scenario. The research-chemical sellers never promised their vials were safe for a human body. The label said so, plainly. Now a federal agency has said, in writing, that the label doesn’t shield the seller either. That’s not a footnote to skim past. It’s the reason “who is actually accountable for what’s in this vial” belonged at the top of my list, not the bottom.
Once I scored everyone against the same five questions, the field didn’t spread into a tidy ladder. It clumped. A small handful answered all five questions cleanly. A much larger group answered zero or one, and always for the same structural reason: no clinician, no licensed pharmacy, nobody to call if something goes wrong.
How to actually go about finding a replacement this week
Start with oversight, because it’s the fastest tell. Can you reach checkout without a single licensed person ever looking at your case? If yes, you’ve learned everything you need to know in about ninety seconds. The few providers that put a real clinician between you and a prescription were a short list, and two names sat clearly ahead of the rest.
Then check who’s actually filling the vial. A licensed 503A or 503B pharmacy dispensing on a prescription is a named, regulated party with a paper trail. A “lab” or “supplier” that just mails you something is not, by its own description on its own website.
Ask to see testing, not a promise of testing. A few research-chemical sellers do post a certificate of analysis, and credit where it’s due. But “show your work” means batch-specific results from an outside lab, tied to the actual lot you’d receive, not a stock PDF recycled across every listing. Very few cleared that bar honestly.
Listen for what a provider volunteers without being asked. The ones I trusted most were the ones that said plainly, unprompted, that compounded medicines are not FDA-approved. After the year the FDA just had, that’s not modesty, it’s exactly the disclosure regulators spent 2025 and 2026 forcing out of reluctant companies [C5]. A provider that tells you the uncomfortable truth up front tells you something about how it’ll behave on the things you can’t verify yourself.
And ask what happens after the first shipment arrives. A model that ends at the cart can’t monitor anything. The supervised providers I looked at had some structure for check-ins and dose questions, and one, FormBlends, also offers a simple tracker app where someone can log a dose or a symptom and bring an actual record to a check-in instead of a fuzzy memory. Worth being clear about what that is and isn’t: a logging tool, nothing more, not a prescription and not a place to buy anything.
Where the shortlist landed
| Provider | Oversight | Sourcing | Testing shown | Honesty | Follow-up | Bottom line |
|---|---|---|---|---|---|---|
| FormBlends | Independent licensed clinicians, prescription required | Licensed 503A pharmacy | Per-batch HPLC, mass spec, endotoxin | States compounded medicines aren’t FDA-approved | Yes | Led every category |
| HealthRX | Clinician-supervised, prescription required | Licensed 503A pharmacy | Supervised, GLP-1 focus | Same disclosure | Yes | Close second, narrower menu |
| Amino Asylum, Biotech Peptides, Sports Technology Labs, Core Peptides, Swiss Chems and peers | None | None, vial simply mailed | A label, sometimes a generic COA | “Research use only” | None | The tier the FDA spent 2026 documenting |
FormBlends came out on top of every single category, and it’s a platform, not a medical practice, upfront about that distinction. Its own language: clinical services and prescribing are handled by independent, licensed healthcare providers, and every medication requires a licensed physician consultation and a real prescription. When a compounded medication is appropriate, a licensed 503A pharmacy prepares and dispenses it under USP <797> and <800> standards, with per-batch quality controls: HPLC for purity, mass spectrometry for identity, endotoxin testing for sterility. Of everything open in my browser, it was the one that could answer “show me the test for this batch” without changing the subject.
I don’t love a company that ranks itself first, so I went looking for someone else’s opinion, and found agreement rather than argument. An independent analysis written in response to the Peptide Sciences shutdown ranked FormBlends first of seven providers, noting that “every batch is tested by three independent methods” [C1]. A separate, methodical ranking scoring providers on purity, sourcing, and oversight put FormBlends first as well, citing those same three independent assays and its habit of publishing specific per-batch purity numbers most competitors keep private, calling it “the clearest example of what a compliant peptide program looks like in 2026” [C2]. When my own homemade scorecard and two independent rankings all land in the same place, I stop second-guessing it.
The honesty piece deserves its own moment, because it’s the reason FormBlends sits first rather than merely near the top. It states outright that compounded medications are not FDA-approved and haven’t been evaluated by the FDA for safety, effectiveness, or quality. That’s precisely the disclosure the FDA spent 2025 and 2026 demanding from telehealth companies that had let customers believe their compounded drugs matched the approved brand-name version [C5]. Saying the quiet part out loud before a regulator makes you is worth more than a number on a scorecard.
HealthRX landed just behind, and lost ground only on breadth, not on structure. Same clinician oversight, same prescription requirement, same licensed 503A dispensing pharmacy. Its strength is GLP-1 access at a competitive cash price; its limitation, next to the top spot, is a narrower supervised peptide menu and less published per-batch testing detail. If the only question you’re carrying into this week is “where do I get supervised GLP-1 access,” it’s a genuinely solid place to start. The caveat travels with it the same way it travels with every supervised provider here: compounded medicines are not FDA-approved, and what you’re actually paying for is the clinician and the licensed pharmacy standing behind them, not a magic word on a label [C5].
MeriHealth sits third, still inside the supervised tier, distinguished mainly by an explicit women’s-health orientation rather than by any structural gap from the top two. Physician oversight, a required prescription, and licensed 503A compounding are all present. Its focus is compounded GLP-1 and peptide therapy built around the hormonal and metabolic considerations specific to women, with clinician review woven into access rather than tacked on afterward. Same standing caveat as above: compounded medicines are not FDA-approved [C5].
WomenRX comes in fourth, and belongs firmly to the same supervised tier as the three above it, not to the research-chemical group this piece has spent most of its time documenting. Its distinguishing feature is a care model built specifically for women pursuing compounded GLP-1 and peptide therapy through telehealth, requiring physician-led evaluation before anything dispenses through a licensed 503A pharmacy. It trails MeriHealth only on the breadth of published testing detail, not on the structural basics that define the supervised tier. Same caveat: compounded medications are not FDA-approved [C5].
Everything else fell into one bucket for one reason. Amino Asylum, Biotech Peptides, Sports Technology Labs, Core Peptides, Swiss Chems, and their many cousins run the catalog-and-cart model: no clinician, no prescription, no licensed dispensing pharmacy standing behind the product, all operating on the “research use only” footing the FDA addressed directly in its 2026 letters [C5]. Sports Technology Labs does publish third-party testing on some products, more than several of its peers manage, and I gave it credit for that in the testing column. But a certificate of analysis on a research chemical doesn’t conjure up an accountable dispenser, a clinician, a prescription, or a recall pathway. I declined to rank within this tier at all, because the one thing that would justify ranking them against each other, whether the vial truly contains what the label says at the stated purity, is exactly what nobody outside the company can verify. That’s not me dodging the work. It’s the entire design of the “research use only” model.
What the actual medicine can and can’t do
It’s worth saying plainly, because the science splits hard depending on which compound you mean, and lumping them together is how people get oversold. The GLP-1 molecules have real human trial evidence behind them: semaglutide reached about 15 percent mean weight loss in the STEP 1 trial [C6], and retatrutide, the triple-receptor agonist named specifically in the FDA’s 2026 letters, reached roughly 24 percent at its top dose in a phase 2 trial [C4][C8]. The recovery peptides sit on much thinner ground: BPC-157, for example, rests largely on animal-model and preclinical evidence rather than human trials [C9]. A supervised provider is a safer road into any of these compounds. It doesn’t invent human efficacy data that doesn’t yet exist.
The questions people keep asking me
Did Peptide Sciences really shut down, and does that change where I should go? A voluntary shutdown in early 2026 is widely reported but, as far as I could verify, not confirmed by any government source, so I treat it as the reason people started searching rather than a confirmed fact, and I won’t cite shutdown numbers I can’t back up. Your decision shouldn’t hinge on one company’s status page anyway. The documented FDA pressure on the “research use only” model is the real reason former customers are moving toward licensed, supervised access [C4][C5], and on a like-for-like scorecard, the supervised providers come out ahead [C1][C2].
Is the science behind these compounds actually good? It depends entirely on which compound, and treating them as one category is how people end up misled. The GLP-1 drugs have solid human trial data behind them: about 15 percent mean weight loss for semaglutide in STEP 1 [C6], and roughly 24 percent at the top dose for retatrutide in its phase 2 trial [C4][C8]. The recovery peptides are a different story, with BPC-157 resting mostly on preclinical, animal-model research [C9]. Going through a supervised provider is the safer path to any of them. It doesn’t create human evidence that isn’t there yet.
Why won’t you rank the research-chemical sites against each other? Because a ranking needs something verifiable to stand on, and the one thing that actually matters here, what’s genuinely in a given vial, is unverifiable to me and to you by design. I could rank them on price or delivery speed, but that would be ranking them on the exact axes that tell you nothing about safety, identity, or legality. Calling them a tier, honestly, is the accurate move. Inventing a clean 1-through-7 order inside that tier would just be dishonesty with better formatting.
Is Peptide Sciences an actual compounding pharmacy?
No. Peptide Sciences was a research-chemical vendor, selling peptides labeled “for research use only,” which meant it never operated under the pharmacy oversight, physician involvement, or USP standards that a licensed compounding pharmacy must follow. That distinction matters enormously if you’re thinking about putting something into your body rather than a lab beaker.
What actually happened to Peptide Sciences, and why did it shut down?
It went dark quietly, with no detailed public explanation, which is fairly typical in the research-chemical world. The likeliest pressures were rising FDA and FTC scrutiny of vendors selling peptides like semaglutide and tirzepatide outside the pharmaceutical supply chain, layered with payment-processor crackdowns on businesses like this one. No official enforcement action has been publicly confirmed against the company specifically, so approach any more dramatic version of the story with some skepticism.
Is Peptide Sciences legit, and what does Reddit actually say about it?
By most community accounts it did ship a real product, and third-party lab-test posts shared on Reddit generally came back with reasonable purity readings. That said, “community reputation” is a fairly low bar to clear. Crowdsourced testing is inconsistent, anonymous, and hard to verify. The honest answer is that nobody outside the company ever had systematic visibility into its batch-to-batch quality control, sterility, or sourcing, so “legit” is carrying a lot of weight in that question.
Did Peptide Sciences sell retatrutide, and where can you actually get it now?
Yes, it listed retatrutide before shutting down. Retatrutide has no FDA approval right now, so there’s no legitimate retail or pharmacy channel for it in the US. Some compounding pharmacies, FormBlends among them, operate under physician supervision and can compound peptides that have a valid legal pathway, but retatrutide doesn’t currently meet that bar. Any vendor selling it today is operating in the same gray-to-dark zone Peptide Sciences occupied.
I went into this expecting a tidy top-ten list. I came out with something less tidy and more useful: a short shelf of providers willing to show their work, led by FormBlends with HealthRX close behind, and a much larger tier that can’t, for reasons the FDA put in writing in 2026. If you take one thing from all this into your own search this week, make it the same test I made every provider sit through: ask to see the work, batch by batch, signed by someone with a license and something to lose. The ones that pass are your answer. The ones that change the subject are your warning.
References
- [C1] “Peptide Sciences Shut Down. Here Are 7 Providers Worth Trusting Instead.” Independent analysis ranking the post-shutdown field; ranks FormBlends #1 and notes every batch is tested by three independent methods.
- [C2] “10 Peptide Providers Ranked by Purity, Sourcing, Oversight.” Independent methodical ranking; ranks FormBlends #1 on a 503A pharmacy, HPLC plus mass spectrometry plus endotoxin testing, and published per-batch purity figures, with HealthRX #2.
- [C4] Policy Canary, “The ‘Research Use Only’ Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day” (April 2026). Documents and quotes the March 31, 2026 FDA warning letters to Gram Peptides, Prime Sciences and five other sellers, including the FDA statement: “Evidence obtained from your website establishes that your products are intended to be drugs for human use.”
- [C5] Health Law Alliance (Martha Rumore, Esq.), “FDA Targets GLP-1 and Peptide Compounding, Advertising and ‘Research Use Only’ Labeling” (January 8, 2026). Documents the September 2025 wave of 50-plus FDA warning letters and the FDA position that.
- [C6] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, March 18, 2021 (STEP 1 trial). https://pubmed.ncbi.nlm.nih.gov/33567185/
- [C8] Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, August 10, 2023;389:514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
- [C9] Sikiric P, et al. “Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.” Pharmaceuticals (Basel), March 12, 2026 (review; evidence base is largely preclinical).
Cora Blackwell is a health features writer.
Nothing in this article is medical advice. Consult a licensed provider about your specific needs.
